Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PLX038 + Rucaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PLX038||PLX038A|PLX-038|PLX 038||TOPO Inhibitor (Pan) 3||PLX038 is a PEG-conjugated form of the topoisomerase inhibitor SN-38 (PMID: 31707444).|
|Rucaparib||Rubraca||AG014699|PF-01367338|CO-388|AG14447||PARP Inhibitor (Pan) 29||Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring a deleterious BRCA mutation, and for treatment in patients with metastatic castration-resistant prostate cancer harboring a deleterious BRCA mutation (germline and/or somatic) who received anti-androgen therapy and a taxane-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM Q1970*||breast ductal carcinoma||predicted - sensitive||PLX038 + Rucaparib||Case Reports/Case Series||Actionable||In a clinical trial, PLX038 and Rubraca (rucaparib) combination treatment resulted in a complete response within the first treatment cycle, followed by PLX038 monotherapy, which resulted in maintenance of tumor suppression for a total of 12 months in a patient with metastatic breast ductal carcinoma harboring germline ATM Q1970* (PMID: 35999657; NCT04209595).||35999657|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04209595||Phase Ib/II||PLX038 + Rucaparib||PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers||Active, not recruiting||USA||0|